Anzeige
Novara — A Smarter Way to Access Global Markets
LIVE-DESK·Globale Marktredaktion

Aktien

Evonik shares jump 4.8% on BASF merger talk reports
AktienArticle

Evonik shares jump 4.8% on BASF merger talk reports

Evonik stock rose nearly 5% after media cited Dealreporter and Mergermarket reports of BASF discussions on a possible transaction, while the firm continues its restructuring plan.

Priya Anand · 22 Sept 2026
Valion Bio regains Nasdaq $1 bid price compliance
AktienArticle

Valion Bio regains Nasdaq $1 bid price compliance

Valion Bio received written notice from Nasdaq confirming it met the $1 minimum bid price requirement after its shares closed at $2.38, up 12.26%, on Sep 21.

Priya Anand · 22 Sept 2026
Enlivex Ends $200M+ Private Placement After Rain Foundation Deal Termination
AktienArticle

Enlivex Ends $200M+ Private Placement After Rain Foundation Deal Termination

Enlivex Ltd. (ENLV) halted a planned $66.7M share sale to Rain Foundation, citing shareholder approval failure and exercising termination rights under the agreement.

Priya Anand · 22 Sept 2026
Scynexis Names Former Akebia Chief Medical Officer to Its Board
AktienArticle

Scynexis Names Former Akebia Chief Medical Officer to Its Board

The clinical-stage biotech has added Steven K. Burke, currently SVP and chief research and development officer at Akebia Therapeutics, to its board of directors effective Sept. 18.

Priya Anand · 22 Sept 2026
PDS Biotech Reports 39.3-Month Median Survival in HPV16 Head-and-Neck Cancer Trial
AktienArticle

PDS Biotech Reports 39.3-Month Median Survival in HPV16 Head-and-Neck Cancer Trial

The Phase 2 VERSATILE-002 study showed a median overall survival of 39.3 months for patients with HPV16-positive recurrent or metastatic head and neck squamous cell carcinoma who were naïve to checkpoint inhibitors and had PD-L1 CPS ≥1. The combination of PDS0101 and pembrolizumab yielded an objective response rate of 36% with a manageable safety profile.

Priya Anand · 22 Sept 2026
Electra AI signs multiple commercial deals ahead of Nasdaq listing
AktienArticle

Electra AI signs multiple commercial deals ahead of Nasdaq listing

Electra AI, valued at about $250 million, announced a series of partnerships with D‑Orbit, Naoris Quantum, Propel Industries, Omega Seiki, MinTech and Mooving as it prepares for a Nasdaq debut via a SPAC merger with Iron Horse Acquisition II.

Priya Anand · 22 Sept 2026
CNSide Diagnostics signs in‑network agreement with Blue Cross Blue Shield of Michigan
AktienArticle

CNSide Diagnostics signs in‑network agreement with Blue Cross Blue Shield of Michigan

CNSide Diagnostics, a Cerenome subsidiary, will provide its CSF tumor cell assay to Blue Cross Blue Shield of Michigan, expanding coverage to about 158 million lives.

Priya Anand · 22 Sept 2026
US-Märkte vor Eröffnung ohne klare Richtung: SMI gedämpft, UBS unter Druck
AktienArticle

US-Märkte vor Eröffnung ohne klare Richtung: SMI gedämpft, UBS unter Druck

Schweizer Aktienindex leidet unter globaler Unsicherheit; UBS fällt unter Regulierungsfragen, während On-Aktien durch Wachstumsprognosen und Rückkaufprogramm unterstützt werden.

Priya Anand · 22 Sept 2026
Beta Bionics and Senseonics Partner on Glucose Monitoring Integration
AktienArticle

Beta Bionics and Senseonics Partner on Glucose Monitoring Integration

Beta Bionics Inc. and Senseonics have partnered to integrate their automated insulin delivery systems with the Eversense 365 continuous glucose monitoring system, expected to launch in Q4 2026.

Priya Anand · 22 Sept 2026
Greenbrier Secures $600M Railcar Order from Saudi Railway
AktienArticle

Greenbrier Secures $600M Railcar Order from Saudi Railway

The Greenbrier Companies secured 3,400 railcar orders valued at $600 million, including a significant Saudi Railway deal for tank cars and intermodal units.

Priya Anand · 22 Sept 2026
Borsa Istanbul to drop over a quarter of BIST-100 constituents
AktienArticle

Borsa Istanbul to drop over a quarter of BIST-100 constituents

More than 25% of the stocks currently in Turkey's BIST-100 benchmark will be removed next month as the exchange tightens eligibility rules, without citing a specific trigger.

Priya Anand · 22 Sept 2026
CollPlant Regains Nasdaq Compliance After Share Price Dips Below $1
AktienArticle

CollPlant Regains Nasdaq Compliance After Share Price Dips Below $1

The Rehovot-based biotech firm restored its Nasdaq listing after its shares closed at or above the $1 minimum for 10 consecutive business days.

Priya Anand · 22 Sept 2026
Arrive AI to Showcase Autonomous Delivery Tech at Investor Event
AktienArticle

Arrive AI to Showcase Autonomous Delivery Tech at Investor Event

The Indiana-based logistics firm will demonstrate its Arrive Point network, AMR handoff system, and simulated drone deliveries during a virtual investor event Wednesday.

Priya Anand · 22 Sept 2026
Wave Life Sciences appoints Monika Vnuk as chief business officer
AktienArticle

Wave Life Sciences appoints Monika Vnuk as chief business officer

Wave Life Sciences has appointed Monika Vnuk to the role of chief business officer.

Priya Anand · 22 Sept 2026
Lantern Pharma Secures Patent for LP-284 Cancer Drug
AktienArticle

Lantern Pharma Secures Patent for LP-284 Cancer Drug

USPTO grants Notice of Allowance for LP-284, targeting mantle cell lymphoma and double-hit lymphoma, with broader claims covering combination therapies and a 2042 patent expiry.

Priya Anand · 22 Sept 2026
Alibaba, Quest Diagnostics, On Holding, GameStop Lead Premarket Moves
AktienArticle

Alibaba, Quest Diagnostics, On Holding, GameStop Lead Premarket Moves

Shares of Alibaba, Quest Diagnostics, On Holding and GameStop are among the standout movers ahead of the opening bell on Tuesday.

Priya Anand · 22 Sept 2026
IDEAYA Biosciences Shares Drop Amid 2026 Pipeline Updates at Citigroup Summit
AktienArticle

IDEAYA Biosciences Shares Drop Amid 2026 Pipeline Updates at Citigroup Summit

IDEAYA Biosciences reported progress on its oncology pipeline, including regulatory milestones for Darovasertib and IDE849, amid a market cap of $3.66 billion and a 55% year-to-date return.

Priya Anand · 22 Sept 2026
ProMIS Neurosciences presents interim Alzheimer's data at Moody Capital; shares climb
AktienArticle

ProMIS Neurosciences presents interim Alzheimer's data at Moody Capital; shares climb

ProMIS reported zero ARIA-E and a 15% p-tau217 drop in its PMN310 interim safety analysis at the Moody Capital conference, sending shares up nearly 8%.

Priya Anand · 22 Sept 2026